Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19694578rdf:typepubmed:Citationlld:pubmed
pubmed-article:19694578lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0034603lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0033572lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0005919lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0013254lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0024337lld:lifeskim
pubmed-article:19694578lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:19694578pubmed:issue4lld:pubmed
pubmed-article:19694578pubmed:dateCreated2009-8-21lld:pubmed
pubmed-article:19694578pubmed:abstractTextGastrin-releasing peptide receptors (GRPRs) are overexpressed on a variety of human tumors, such as prostate, breast, and lung cancer. Bombesin (BN) is a 14-amino-acid peptide with high affinity for these GRPRs. We synthesized DTPA-Q-K-Y-G-N-Q-W-A-V-G-H-L-M, a 13-amino-acid peptide chelated with diethylenetriaminepentaacetic acid (DTPA), and radiolabeled this BN analog with 111InCl(3). Biologic activity of 111In-[DTPA(1), Lys(3), Tyr(4)]-BN was evaluated in PC-3 prostate tumor-bearing severely compromised immunodeficient (SCID) mice. The purity of synthesized [DTPA(1), Lys(3), Tyr(4)]-BN was greater than 95%. The radiolabeling efficiency of 111In-[DTPA(1), Lys(3), Tyr(4)]-BN was 96.9% +/- 2.46%. The IC(50) and K(i) of [DTPA(1), Lys(3), Tyr(4)]-BN in the human bombesin 2 receptor were 1.05 +/- 0.46 and 0.83 +/- 0.36 nM, respectively. The K(d) of 111In-[DTPA(1), Lys(3), Tyr(4)]-BN in GRPR-expressing PC-3 tumor cells was 22.9 +/- 6.81 nM. Both biodistribution and micro-SPECT/CT (single-photon emission computed tomography/computed tomography) imaging studies with 111In-[DTPA(1), Lys(3), Tyr(4)]-BN demonstrated the highest uptake at 8 hours postinjection. The Pearson correlation analysis showed a positive correlation of tumor uptake between biodistribution and micro-SPECT/CT semiquantification imaging analysis (r = 0.832). Our results revealed 111In-[DTPA(1), Lys(3), Tyr(4)]-BN has high affinity with BN type 2 receptor. The results demonstrated a good uptake in the GRPR-overexpression of PC-3 tumor-bearing SCID mice. 111In-[DTPA(1), Lys(3), Tyr(4)]-BN is a potential agent for imaging GRPR-positive tumors in humans.lld:pubmed
pubmed-article:19694578pubmed:languageenglld:pubmed
pubmed-article:19694578pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19694578pubmed:citationSubsetIMlld:pubmed
pubmed-article:19694578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19694578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19694578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19694578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19694578pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19694578pubmed:statusMEDLINElld:pubmed
pubmed-article:19694578pubmed:monthAuglld:pubmed
pubmed-article:19694578pubmed:issn1557-8852lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:StabinMichael...lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:JanMeei-LingM...lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:LinWuu-JyhWJlld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:LeeTe-WeiTWlld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:ChangChih-Hsi...lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:ChenLiang-Che...lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:HsuWei-ChuanW...lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:LeeWan-ChiWClld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:HoChung-LiCLlld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:YehChung-Hsin...lld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:WuYu-HsienYHlld:pubmed
pubmed-article:19694578pubmed:authorpubmed-author:ChiuShu-PeiSPlld:pubmed
pubmed-article:19694578pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19694578pubmed:volume24lld:pubmed
pubmed-article:19694578pubmed:ownerNLMlld:pubmed
pubmed-article:19694578pubmed:authorsCompleteYlld:pubmed
pubmed-article:19694578pubmed:pagination435-43lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:meshHeadingpubmed-meshheading:19694578...lld:pubmed
pubmed-article:19694578pubmed:year2009lld:pubmed
pubmed-article:19694578pubmed:articleTitleReceptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.lld:pubmed
pubmed-article:19694578pubmed:affiliationInstitute of Nuclear Energy Research, Taoyuan, Taiwan, Republic of China.lld:pubmed
pubmed-article:19694578pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19694578lld:pubmed